ADH1B
All-trans-retinol dehydrogenase [NAD
As of the edition of 20 October 2026, ADH1B (all-trans-retinol dehydrogenase [NAD, UniProt P00325) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00325
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 9
- Disease areas
- Chemically induced; Digestive system; Eye; Inherited and neonatal; Mental health
- Registered trials of its drugs
- 5
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Withdrawn from market | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fomepizole | Marketed | Phase 2 | Ends 2027 |
| Nitrefazole | Withdrawn from market | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Takeda | Route B |
The other 1 company at ADH1B
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at ADH1B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.